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Background
Our laboratory has shown that phosphodiesterase-5
(PDE-5) inhibitors including sildenafil, vardenafil and
tadalafil induce powerful protection against myocardial
ischemia-reperfusion injury. We have shown that sildena-
fil protects through activation PKC, expression of eNOS/
iNOS, protein kinase G (PKG) and opening of mitochon-
drial KATP (mitoKATP) channels [1]. Hydrogen sulfide
(H2S) is a gaseous molecule that is produced enzymati-
cally and exerts physiological actions in the cardiovascular
system. Similar to PKG, H2S has been shown to protect
the heart via opening of mitoKATP channel [2]. In the cur-
rent study, we hypothesized that tadalafil, the long acting
inhibitor of PDE-5 mediates cardioprotection through
H2S signaling in a PKG-dependent fashion.
Methods and results
After baseline transthoracic echocardiography (TTE),
adult ICR mice were injected i.p. with vehicle (10%
DMSO) or tadalafil (1 mg/kg) with or without KT5823
(KT, PKG blocker, 1 mg/kg) or dl-propargylglycine [PAG,
Cystathionine-γ-lyase (CSE, H2S-producing enzyme)
blocker; 50 mg/kg] 1 h prior to coronary artery ligation for
30 min and reperfusion for 24 h, whereas C57BL-wild
type and CSE-knockout mice were treated with either
vehicle or tadalafil. After reperfusion, TTE was performed
and hearts were collected for infarct size (IS) measure-
ment using TTC staining. Survival was increased with
tadalafil (95%) compared with control (65%, P < 0.05).
Infarct size was reduced with tadalafil (13.2 ± 1.7%) com-
pared to vehicle (40.6 ± 2.5%; P < 0.05). KT and PAG
abolished tadalafil-induced protection (IS: 39.2 ± 1% and
51.2 ± 2.4%, respectively) similar to genetic deletion of
CSE (47.2 ± 5.1%). Moreover, tadalafil preserved frac-
tional shortening (FS: 31 ± 1.5%) compared to control
(FS: 22 ± 4.8%, P < 0.05). Baseline FS was 44 ± 1.7%. KT
and PAG abrogated the preservation of LV function with
tadalafil by decline in FS to 17 ± 1% and 23 ± 3%, respec-
tively. Compared to vehicle, myocardial H2S production
was significantly increased with tadalafil and was abol-
ished with KT.
Conclusion
PKG activation with tadalafil limits myocardial infarction
and preserves LV function through H2S signaling.
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